Mark Harrison

Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial

Gary Middleton, Paul Silcocks, Trevor F. Cox et al. · The Lancet Oncology · 2014 · 374 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial

Susan Dutton, David Ferry, Jane Blazeby et al. · The Lancet Oncology · 2014 · 330 citations · Full text

Medicine, Oncology, Pharmacology +6

Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study

Timothy Iveson, Ross C. Donehower, S. Tjulandin et al. · The Lancet Oncology · 2014 · 261 citations

Medicine, Oncology, Pharmacology +15

3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial

Timothy Iveson, Rachel Kerr, Mark Saunders et al. · The Lancet Oncology · 2018 · 188 citations · Full text

Medicine, Oncology, Pharmacology +16

Gefitinib and <i>EGFR</i> Gene Copy Number Aberrations in Esophageal Cancer

Russell Petty, Åsa Dahle-Smith, David A. Stevenson et al. · Journal of Clinical Oncology · 2017 · 140 citations · Full text

Medicine, Molecular Genetics, Oncology +17